Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Thomas Wiegel | Colin C Pritchard | Stefano Fanti | Oliver Sartor | Susan Halabi | Nicolas Mottet | Gerhardt Attard | Mark A Rubin | Fred Saad | Gedske Daugaard | Himisha Beltran | Christopher P Evans | Alberto Bossi | Raja B Khauli | Mark Frydenberg | P. Kantoff | I. Tannock | M. Rubin | M. Sydes | M. Gleave | F. Saad | R. Eeles | C. Parker | R. Bristow | H. Beltran | C. Drake | M. Morris | H. Scher | W. Oh | S. Fanti | A. Padhani | M. Roach | T. Wiegel | F. Feng | C. Higano | B. Tombal | C. Sternberg | C. Logothetis | B. Carver | N. Clarke | G. Kramer | M. Frydenberg | C. Pritchard | I. Davis | O. Sartor | A. Morgans | D. Castellano | A. Heidenreich | C. Sweeney | K. Fizazi | R. Valdagni | N. Mottet | T. Beer | E. Efstathiou | C. Ryan | J. D. de Bono | G. Attard | C. Evans | S. Halabi | H. Soule | S. Gillessen | P. Ost | A. Bossi | G. Daugaard | N. Shore | V. Murthy | Celestia S Higano | Johann de Bono | William Oh | Anwar R Padhani | Philip Kantoff | Matthew R Sydes | Riccardo Valdagni | Piet Ost | Noel Clarke | Felix Feng | A. Omlin | Matthew R. Smith | Vedang Murthy | Mack Roach | Cora N Sternberg | Aurelius Omlin | Hiroyoshi Suzuki | Silke Gillessen | Tomasz M Beer | Rob Bristow | Brett Carver | Daniel Castellano | Byung Ha Chung | Ian D Davis | Rodolfo Borges Dos Reis | Charles G Drake | Ros Eeles | Eleni Efstathiou | Karim Fizazi | Martin Gleave | Axel Heidenreich | Nicolas James | Pirkko-Liisa Kellokumpu-Lehtinen | Gero Kramer | Chris Logothetis | Fernando Maluf | Alicia K Morgans | Michael J Morris | Chris Parker | Charles Ryan | Howard Scher | Avishay Sella | Neal Shore | Matthew Smith | Howard Soule | Christopher Sweeney | Ian Tannock | Bertrand Tombal | R. Khauli | B. Chung | A. Sella | Hiroyoshi Suzuki | N. James | P. Kellokumpu-Lehtinen | F. Maluf | Rodolfo Borges dos Reis

[1]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[2]  N. Magné,et al.  Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. , 2019, The Lancet. Oncology.

[3]  M. Parmar,et al.  Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. , 2019, European urology.

[4]  M. Gleave,et al.  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. , 2019, The Lancet. Oncology.

[5]  Jun Luo,et al.  Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[6]  V. Khoo,et al.  New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly. , 2019, Clinical radiology.

[7]  D. Murphy,et al.  Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. , 2019, European urology oncology.

[8]  M. Stockler,et al.  TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) , 2019, BJU international.

[9]  M. Gleave,et al.  Towards precision oncology in advanced prostate cancer , 2019, Nature Reviews Urology.

[10]  N. Agarwal,et al.  PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations , 2019, Annals of Oncology.

[11]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[12]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[13]  M. Sydes,et al.  Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  F. Saad,et al.  Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer , 2019, Clinical Cancer Research.

[15]  N. Van As,et al.  Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer , 2019, World Journal of Urology.

[16]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Harrison,et al.  Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer , 2019, Cancer medicine.

[18]  M. Graefen,et al.  Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. , 2019, European urology.

[19]  M. Terris,et al.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.

[20]  M. Parmar,et al.  Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis , 2019, European urology.

[21]  W. Oyen,et al.  Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. , 2019, Radiology.

[22]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[23]  M. Graefen,et al.  External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. , 2019, European urology.

[24]  F. Alongi,et al.  Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). , 2019, Critical reviews in oncology/hematology.

[25]  Frederico Leal,et al.  Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.

[26]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[27]  H. Beltran,et al.  Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[28]  J. Bono,et al.  TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. , 2019, Journal of Clinical Oncology.

[29]  L. Collette,et al.  Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. , 2019, Journal of Clinical Oncology.

[30]  M. Morris,et al.  VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). , 2019 .

[31]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[32]  S. Fanti,et al.  The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[33]  F. Cavalli,et al.  All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[34]  J. Gregg,et al.  Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors , 2019, JCO precision oncology.

[35]  P. Ghosh,et al.  Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer1 , 2019, Translational oncology.

[36]  A. D'Amico,et al.  American Urological Association (AUA) Guideline ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: ASTRO/AUA GUIDELINE , 2013 .

[37]  L. Marchionni,et al.  CDK12 inactivation across solid tumors: an actionable genetic subtype , 2019, Oncoscience.

[38]  Ronald C. Chen,et al.  A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. , 2019, European urology oncology.

[39]  P. Boutros,et al.  The influence of BRCA2 mutation on localized prostate cancer , 2019, Nature Reviews Urology.

[40]  P. Nelson,et al.  Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. , 2019, JCO precision oncology.

[41]  R. Nussbaum,et al.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.

[42]  F. Saad,et al.  Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[43]  P. Kantoff,et al.  Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade , 2019, JAMA oncology.

[44]  N. V. As,et al.  Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer , 2019, Current Oncology Reports.

[45]  S. Gregory,et al.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Zwinderman,et al.  Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. , 2019, European urology.

[47]  F. Saad,et al.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[48]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[49]  R. Berger,et al.  Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199. , 2019, Journal of Clinical Oncology.

[50]  D. Murphy,et al.  Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[52]  I. Tannock,et al.  Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Miralbell,et al.  Oligometastatic prostate cancer: The game is afoot. , 2019, Cancer treatment reviews.

[54]  S. Pignata,et al.  PARP inhibitors in ovarian cancer. , 2019, Cancer treatment reviews.

[55]  A. Partin,et al.  Adjuvant radiation with androgen‐deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit , 2019, BJU international.

[56]  E. Crawford,et al.  A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III) , 2019, The Journal of urology.

[57]  A. Chinnaiyan,et al.  Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency , 2019, European urology.

[58]  R. Weichselbaum,et al.  Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.

[59]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[60]  W. Oyen,et al.  Consensus on molecular imaging and theranostics in prostate cancer. , 2018, The Lancet. Oncology.

[61]  D. Low,et al.  Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial , 2018, International Journal of Radiation Oncology*Biology*Physics.

[62]  E. Kessler.  Management of Metastatic Prostate Cancer in Frail/Elderly Patients. , 2018, Oncology.

[63]  Ryan L. Smith,et al.  Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials , 2018, International Journal of Radiation Oncology*Biology*Physics.

[64]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[65]  F. Saad,et al.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[66]  H. Scher,et al.  Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[68]  E. Chan,et al.  Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer. , 2018, Cancer research.

[69]  F. Cappuccio,et al.  Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience , 2018, Prostate international.

[70]  M. Rubin,et al.  Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer , 2018, The Journal of clinical investigation.

[71]  P. Kantoff,et al.  Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) , 2018, The Prostate.

[72]  M. Menon,et al.  Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. , 2018, European urology.

[73]  D. Murphy,et al.  Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 , 2018, BJU international.

[74]  A. Thiery-Vuillemin,et al.  Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study , 2018, ESMO Open.

[75]  D. Murphy,et al.  Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. , 2018, The Urologic clinics of North America.

[76]  D. Lam,et al.  Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia , 2018, Asia-Pacific journal of clinical oncology.

[77]  P. Kantoff,et al.  The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer , 2018, The Journal of urology.

[78]  A. Tewari,et al.  Intratumor heterogeneity in prostate cancer. , 2018, Urologic oncology.

[79]  M. Borre,et al.  Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Saad,et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.

[81]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[82]  D. Bailey,et al.  A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol , 2018, BJU international.

[83]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[84]  T. Schlomm,et al.  Long‐term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence , 2018, The Prostate.

[85]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[86]  R. DiPaola,et al.  Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. , 2018, European urology.

[87]  J. Epstein,et al.  Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. , 2018, European urology oncology.

[88]  M. Cooperberg,et al.  Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. , 2018, European urology oncology.

[89]  E. Antonarakis,et al.  PARP inhibitors for homologous recombination-deficient prostate cancer , 2018, Expert opinion on emerging drugs.

[90]  M. Ratain,et al.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Maarten J. IJzerman,et al.  Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. , 2018, European urology oncology.

[92]  F. Saad,et al.  ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). , 2018 .

[93]  M. Parmar,et al.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[95]  I. Virgolini,et al.  Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211. , 2018, European urology.

[96]  M. Cooperberg,et al.  A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. , 2018, European urology.

[97]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Kantoff,et al.  Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  A. Zietman,et al.  Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. , 2017, European urology.

[101]  P. Scardino,et al.  Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. , 2017, European urology.

[102]  R. Newton,et al.  Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases , 2017, Medicine and science in sports and exercise.

[103]  M. Aapro,et al.  Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. , 2017, European urology.

[104]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[105]  A. Ashworth,et al.  Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. , 2017, Cancer discovery.

[106]  S. Gabriel,et al.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. , 2017, Cancer discovery.

[107]  P. Werbrouck,et al.  Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. , 2017, European urology.

[108]  F. Montorsi,et al.  Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. , 2017, European urology.

[109]  I. Tannock,et al.  Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[110]  R. Newton,et al.  Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial. , 2017, European urology.

[111]  M. Nykter,et al.  Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. , 2017, European urology.

[112]  M. Menon,et al.  The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. , 2017, European urology.

[113]  Vinay Prasad,et al.  Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings , 2017, Mayo Clinic proceedings.

[114]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[115]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[116]  J. Botelho,et al.  Accuracy-based proficiency testing for testosterone measurements with immunoassays and liquid chromatography-mass spectrometry. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[117]  Zachary J. Heins,et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.

[118]  J. McKenney,et al.  Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[119]  D. Beyer,et al.  A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). , 2017, International journal of radiation oncology, biology, physics.

[120]  N. Dawson,et al.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. , 2017, American health & drug benefits.

[121]  M. Carducci,et al.  Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer , 2017, Cancer.

[122]  M. Kattan,et al.  An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[123]  Q. Ng,et al.  Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer. , 2017, Annals of the Academy of Medicine, Singapore.

[124]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[125]  D. Collins,et al.  Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. , 2017, Radiology.

[126]  S. Kroeze,et al.  SBRT for oligoprogressive oncogene addicted NSCLC. , 2017, Lung cancer.

[127]  M. Hofman,et al.  Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. , 2017, PET clinics.

[128]  Mahul B Amin,et al.  Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2017, The American journal of surgical pathology.

[129]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[130]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[131]  M. Menon,et al.  Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. , 2017, European urology.

[132]  G. Jenster,et al.  The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.

[133]  R. Mehra,et al.  Very Early Salvage Radiotherapy Improves Distant Metastasis‐Free Survival , 2017, The Journal of urology.

[134]  Frode Willoch,et al.  Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer , 2017, The Journal of urology.

[135]  Colin C Pritchard,et al.  DNA Repair in Prostate Cancer: Biology and Clinical Implications. , 2017, European urology.

[136]  F. Montorsi,et al.  Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer , 2017, The Journal of urology.

[137]  K. Cooney,et al.  Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death , 2017 .

[138]  J. Mortensen,et al.  Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database , 2017, Prostate Cancer and Prostatic Diseases.

[139]  M. Harkenrider,et al.  Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer: A Meta-Analysis , 2017, American journal of clinical oncology.

[140]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[141]  Adam D. DePriest,et al.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. , 2017, European urology.

[142]  J. Bono,et al.  Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL , 2017, Prostate Cancer and Prostatic Diseases.

[143]  David P. Smith,et al.  Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  A. Aprikian,et al.  Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[146]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[147]  John D. Roberts,et al.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial , 2017, JAMA.

[148]  E. Sala,et al.  METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer , 2017, European urology.

[149]  P. Carroll,et al.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience , 2017, The Journal of Nuclear Medicine.

[150]  A. Howell,et al.  How to Manage the Obese Patient With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[152]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[153]  Shree Agrawal,et al.  Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  P. Nelson,et al.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate , 2016, Oncotarget.

[155]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[156]  Heather K. Neilson,et al.  Physical Activity and Survival After Prostate Cancer. , 2016, European urology.

[157]  Ronald C. Chen,et al.  Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  Joel T Dudley,et al.  Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  I. Thompson,et al.  Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  P. Nelson,et al.  Mismatch repair enzyme expression in primary and castrate resistant prostate cancer , 2016, Asian journal of urology.

[162]  P. Kantoff,et al.  Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer , 2016, Clinical Cancer Research.

[163]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[164]  Kirsten L. Greene,et al.  Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. , 2016, Future oncology.

[165]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[166]  D. Edwards,et al.  Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation , 2016, Nature Cell Biology.

[167]  P. Nelson,et al.  Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[168]  M. Joerger,et al.  Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[169]  B. Dubray,et al.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. , 2016, The Lancet. Oncology.

[170]  M. Stockler,et al.  Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. , 2016, The Lancet. Oncology.

[171]  M. Gleave,et al.  Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). , 2016 .

[172]  P. Kantoff,et al.  Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression , 2016, Proceedings of the National Academy of Sciences.

[173]  M. Fishman,et al.  Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison , 2016, Supportive Care in Cancer.

[174]  L. Bresler*,et al.  Prevalence of Hypogonadism in Low-Risk Prostate Cancer Survivors. , 2016, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[175]  Jonathan E. Shoag,et al.  Clinical variability and molecular heterogeneity in prostate cancer , 2016, Asian journal of andrology.

[176]  N. James,et al.  Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. , 2016, JAMA oncology.

[177]  G. Scagliotti,et al.  Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[178]  R. Knuechel,et al.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[179]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[180]  D. Beyersdorff,et al.  Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management , 2016, World Journal of Urology.

[181]  S. Chambers,et al.  Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men. , 2016, The journal of sexual medicine.

[182]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[183]  M. Parmar,et al.  Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. , 2016, JAMA oncology.

[184]  M. Parmar,et al.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.

[185]  A. Armstrong,et al.  Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[186]  A. Villers,et al.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. , 2016, The Lancet. Oncology.

[187]  F. Montorsi,et al.  Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. , 2016, European urology.

[188]  D. Levine,et al.  Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. , 2016, Cell reports.

[189]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[190]  E. Kauppila,et al.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial , 2016, Acta oncologica.

[191]  R. Eeles,et al.  Germline genetic profiling in prostate cancer: latest developments and potential clinical applications , 2015, Future science OA.

[192]  E. Morii,et al.  The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer , 2015, Scientific Reports.

[193]  Valentina Taviani,et al.  Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[194]  Steve Y. Cho,et al.  Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies , 2015, Tomography.

[195]  L. Trojan,et al.  Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy , 2015, EJNMMI Research.

[196]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[197]  N. Magné,et al.  Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience , 2015, Chemotherapy.

[198]  K. Baggerly,et al.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.

[199]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[200]  A. Rosenkrantz,et al.  Imaging and evaluation of patients with high-risk prostate cancer , 2015, Nature Reviews Urology.

[201]  S. Fanti,et al.  Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[202]  B. Wullich,et al.  Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis , 2015, BMJ Open.

[203]  J. Carles,et al.  Efficacy and Safety of Abiraterone Acetate in Elderly ( ≥ 75 Years ) Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer , 2015 .

[204]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[205]  I. Mittra,et al.  Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. , 2015, The Lancet. Oncology.

[206]  V. Flamand,et al.  Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. , 2015, The Journal of urology.

[207]  M. McGurk,et al.  New cancer therapies and jaw necrosis , 2015, BDJ.

[208]  M. Fishman,et al.  Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. , 2015, The Journal of urology.

[209]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[210]  R. Eeles,et al.  Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. , 2015, European urology.

[211]  A. Ravaud,et al.  Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. , 2015, European urology.

[212]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[213]  C. Bailly,et al.  Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[214]  A. Ravaud,et al.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. , 2015, The Lancet. Oncology.

[215]  S. Chambers,et al.  A randomised controlled trial of a couples‐based sexuality intervention for men with localised prostate cancer and their female partners , 2015, Psycho-oncology.

[216]  Vladimir Vacic,et al.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.

[217]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[219]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[220]  A. Haese*,et al.  External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. , 2015, The Journal of urology.

[221]  K. Pittman,et al.  Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[222]  J. Patard,et al.  Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. , 2015, Urologic oncology.

[223]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[224]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[225]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[226]  P. Kantoff,et al.  Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  S. Hughes,et al.  The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people , 2015, British Journal of Cancer.

[228]  K. Pienta,et al.  The biology and treatment of oligometastatic cancer , 2015, Oncotarget.

[229]  F. Montorsi,et al.  PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÏVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY , 2015 .

[230]  E. Scarpi,et al.  Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[231]  H. Wong,et al.  Docetaxel in very elderly men with metastatic castration-resistant prostate cancer , 2015, Prostate international.

[232]  D. Poon,et al.  Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer , 2015, Prostate international.

[233]  D. Dearnaley,et al.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  A. Jemal,et al.  Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. , 2015, Journal of the National Cancer Institute.

[235]  U. Capitanio,et al.  More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. , 2015, European urology.

[236]  C. Rübe,et al.  Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. , 2015, International journal of radiation oncology, biology, physics.

[237]  F. Zhou,et al.  A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer , 2015, PloS one.

[238]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  J. Moul,et al.  NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. , 2014, Urology.

[240]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[241]  D. Dearnaley,et al.  Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone , 2014, British Journal of Cancer.

[242]  C. Roehrborn,et al.  Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis , 2014, BJU international.

[243]  Ming Yu,et al.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer , 2014, Nature Communications.

[244]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[245]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[246]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[247]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[248]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[249]  N. Lawrentschuk,et al.  Uro‐oncology multidisciplinary meetings at an Australian tertiary referral centre – impact on clinical decision‐making and implications for patient inclusion , 2014, BJU international.

[250]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[251]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[252]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[253]  F. Montorsi,et al.  [11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[254]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[255]  R. Newton,et al.  A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. , 2014, European urology.

[256]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[257]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  B. Feldman,et al.  Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.

[259]  S. Fosså,et al.  Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. , 2014, European journal of cancer.

[260]  F. Montorsi,et al.  External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. , 2014, Journal of endourology.

[261]  R. Eeles,et al.  Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease , 2014, British Journal of Cancer.

[262]  N. Tunariu,et al.  Visceral disease in castration-resistant prostate cancer. , 2014, European urology.

[263]  B. Tombal,et al.  Can we improve the definition of high‐risk, hormone naïve, non‐metastatic prostate cancer? , 2014, BJU international.

[264]  A. Hinev,et al.  Validation of Nomograms Predicting Lymph Node Involvement in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection , 2014, Urologia Internationalis.

[265]  I. Tannock,et al.  Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[266]  L. Walker,et al.  Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. , 2013, Clinical genitourinary cancer.

[267]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[268]  L. Salomon,et al.  Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. , 2013, The Journal of urology.

[269]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[270]  P. de Souza,et al.  Primary treatment of the prostate improves local palliation in men who ultimately develop castrate‐resistant prostate cancer , 2013, BJU international.

[271]  O. Ogawa,et al.  Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients , 2013, International Journal of Clinical Oncology.

[272]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[273]  P. Nguyen,et al.  Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. , 2013, Seminars in radiation oncology.

[274]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[275]  P. Thall,et al.  Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[276]  D. Rubello,et al.  Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.

[277]  S. Chambers,et al.  Intervening to improve psychological outcomes for men with prostate cancer , 2013, Psycho-oncology.

[278]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[279]  S. Freedland,et al.  Obesity and prostate cancer: weighing the evidence. , 2013, European urology.

[280]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[281]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[282]  H. Joensuu,et al.  2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[283]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[284]  M. Roach,et al.  Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? , 2012, Journal of the National Cancer Institute. Monographs.

[285]  Sridhar Ramaswamy,et al.  Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. , 2012, Cancer discovery.

[286]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[287]  F. Montorsi,et al.  Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. , 2012, European urology.

[288]  M. Gleave,et al.  Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. , 2012, The Journal of urology.

[289]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[290]  H. Amthauer,et al.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.

[291]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[292]  A. Heijboer,et al.  Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. , 2012, The Journal of urology.

[293]  D. Easton,et al.  Germline BRCA1 mutations increase prostate cancer risk , 2012, British Journal of Cancer.

[294]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[295]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[296]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[297]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, Lancet.

[298]  Qiang Hu,et al.  Tumor-Derived G-CSF Facilitates Neoplastic Growth through a Granulocytic Myeloid-Derived Suppressor Cell-Dependent Mechanism , 2011, PloS one.

[299]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[300]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[301]  S. Larson,et al.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen , 2011, Proceedings of the National Academy of Sciences.

[302]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[303]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[304]  I. Tannock,et al.  Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[306]  M. Garzotto,et al.  Acupuncture for hot flashes in patients with prostate cancer. , 2010, Urology.

[307]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[308]  H. Vesper,et al.  Toward excellence in testosterone testing: a consensus statement. , 2010, The Journal of clinical endocrinology and metabolism.

[309]  J. Botelho,et al.  Standardization of testosterone measurements in humans , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[310]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[311]  J. Gschwend,et al.  Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. , 2010, European urology.

[312]  L. Salomon,et al.  Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. , 2010, The Lancet. Oncology.

[313]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2010, Journal of the National Cancer Institute.

[314]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[315]  William Berry,et al.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[316]  P. Warde,et al.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[317]  F. Montorsi,et al.  Pelvic lymph node dissection in prostate cancer. , 2009, European urology.

[318]  A. Italiano,et al.  Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. , 2009, European urology.

[319]  P. Jacobsen,et al.  Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer , 2009, Psycho-oncology.

[320]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[321]  I. Osman,et al.  Molecular mechanisms involving prostate cancer racial disparity. , 2009, American journal of translational research.

[322]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[323]  E. Ernst,et al.  Acupuncture for treating hot flushes in men with prostate cancer: a systematic review , 2009, Supportive Care in Cancer.

[324]  B. Tombal,et al.  Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. , 2008, European urology.

[325]  P Ghadirian,et al.  Rapid progression of prostate cancer in men with a BRCA2 mutation , 2008, British Journal of Cancer.

[326]  T. Rebbeck,et al.  Evaluation of prostate cancer characteristics in four populations worldwide. , 2008, The Canadian journal of urology.

[327]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[328]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[329]  Thorunn Rafnar,et al.  Prostate cancer progression and survival in BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[330]  H. Raff,et al.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. , 2007, The Journal of clinical endocrinology and metabolism.

[331]  Kazunori Nosaka,et al.  Resistance training and reduction of treatment side effects in prostate cancer patients. , 2006, Medicine and science in sports and exercise.

[332]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[333]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[334]  Rashmi Kumar,et al.  NCCN Task Force Report: Bone Health in Cancer Care. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[335]  D. Nathan,et al.  Insulin sensitivity during combined androgen blockade for prostate cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[336]  R. Freedman.  Hot flashes: behavioral treatments, mechanisms, and relation to sleep. , 2005, The American journal of medicine.

[337]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[338]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[339]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[340]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[341]  Kota Takahashi,et al.  Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy , 2004, International journal of urology : official journal of the Japanese Urological Association.

[342]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[343]  K. Courneya,et al.  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[344]  N. Aaronson,et al.  Health related quality of life in men with prostate cancer. , 2003, The Journal of urology.

[345]  F. Saad.  Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. , 2002, Clinical prostate cancer.

[346]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[347]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[348]  Anthony L Zietman,et al.  Changes in body composition during androgen deprivation therapy for prostate cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[349]  D. English,et al.  Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. , 2001, American journal of human genetics.

[350]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[351]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[352]  J. Baniel,et al.  Antiandrogen withdrawal syndrome with cyproterone acetate. , 1998, Urology.

[353]  W. Akerley,et al.  Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer , 1997 .

[354]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[355]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[356]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[357]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[358]  M. Hammar,et al.  Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. , 1994, The Journal of urology.

[359]  C. Reading,et al.  Hot flushes are induced by thermogenic stimuli. , 1989, British journal of urology.

[360]  J. Cho,et al.  Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. , 2018, European urology.

[361]  R. Hicks,et al.  Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.

[362]  A. Villers,et al.  Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial , 2018, The Journal of urology.

[363]  P. Kantoff,et al.  Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[364]  N. Shah,et al.  Association Between Androgen Deprivation Therapy and Risk of Dementia , 2017, JAMA oncology.

[365]  M. Rubin,et al.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.

[366]  N. Corcoran,et al.  Androgen synthesis in prostate cancer: do all roads lead to Rome? , 2017, Nature Reviews Urology.

[367]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[368]  C. Collins,et al.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.

[369]  K. Nikolaou,et al.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[370]  Jonathan I. Epstein,et al.  WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .

[371]  P. Nelson,et al.  Biallelic Inactivation of BRCA 2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer , 2016 .

[372]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[373]  E. Scarpi,et al.  18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[374]  J. Bono,et al.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer , 2015, Nature Reviews Urology.

[375]  S. Vasanawala,et al.  Prospective Comparison of 99 mTc-MDP Scintigraphy , Combined 18 F-NaF and 18 F-FDG PET / CT , and Whole-Body MRI in Patients with Breast and Prostate Cancer , 2015 .

[376]  R. Eeles,et al.  Germline BRCA 1 mutations increase prostate cancer risk , 2015 .

[377]  P. Scardino,et al.  Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. , 2014, European urology.

[378]  A. Ravaud,et al.  A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. , 2012, European journal of cancer.

[379]  K. Cooney,et al.  Male reproductive cancers : epidemiology, pathology and genetics , 2010 .

[380]  Shou-En Lu,et al.  Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[381]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[382]  Leuprolide versus diethylstilbestrol for metastatic prostate cancer. , 1984, The New England journal of medicine.